Skip to main content

Table 1 Baseline characteristics of patients with and without LAAT confirmed on TEE

From: Global peak left atrial longitudinal strain assessed by transthoracic echocardiography is a good predictor of left atrial appendage thrombus in patients in sinus rhythm with heart failure and very low ejection fraction – an observational study

 All patients (n = 63)With LAAT
(n = 20, 31.7%)
Without LAAT
(n = 43, 68.3%)
p-value
Age (years)61.9(±10.9)62.8(±9.9)61.5(±11.4)0.67
Male sex60(95.2%)20(100%)40(93%)0.57
Heart rate (bpm)77.3(±10.9)76.0(±10.8)78.0(±11.1)0.51
BMI (kg/m2)26.2(±4.5)26.1(±4.7)26.3(±4.5)0.83
BSA (m2)1.9(±0.2)1.9(±0.2)1.9(±0.2)0.4
Ischaemic HF aetiology33(52.4%)13(65%)20(46.5%)0.17
Hypertension34(54%)11(55%)23(53.5%)0.91
Diabetes21(33.3%)5(25%)16(37.2%)0,34
Chronic kidney disease28(44.4%)9(45%)19(44.2%)0.95
History of stroke or TIA7(11.1%)3(15%)4(9.3%)0.81
CHA2DS2-VASc score3(2–4)3(2–5)3(2–4)0.65
NYHA class      0.59
 I0(0%)0(0%)0(0%) 
 II7(11.1%)3(15%)4(9.3%) 
 III34(54%)9(45%)25(58.1%) 
 IV22(34.9%)8(40%)14(32.6%) 
Aspirin52(82.5%)17(85%)35(81.4%)0.99
Other antiplatelet agent11(17.5%)6(30%)5(11.6%)0.15
Statin39(61.9%)12(60%)27(62.8%)0.83
Diuretic62(98.4%)19(95%)43(100%)0.69
Beta-blocker58(92.1%)18(90%)40(93%)0.93
ACE-I or ARB43(68.3%)16(80%)27(62.8%)0.17
MRA53(84.1%)16(80%)37(86.1%)0.81
Calcium channel blocker2(3.2%)0(0%)2(4.7%)0.84
Digoxin2(3.2%)0(0%)2(4,7%)0.84
LA diameter (cm)5.0(±0.4)5.0(±0.3)5.1(±0.5)0.6
LAA (cm2)31.3(±7.4)31.1(±5.5)31.4(±8.1)1
LAVI (ml/m2)62.1(±13.3)68.6(±9.9)59.1(±13.7)0.01
LVEF (%)19.2(±4.1)18.9(±5)19.4(±3.7)0.99
E/A2.4(±1.1)2.7(±1.3)2.3(±1)0.28
E/e`24.2(±8.4)23.6(±8.3)24.5(±8.5)0.66
Global PALS (%)8.9(±2)7.2(±2.1)9.7(±1.3)< 0.001
Global PACS (%)−4.0(±1.2)−3.6(±1.1)−4.2(±1.2)0.04
  1. Values are means (± standard deviations), median (interquartile range) or counts (%)
  2. LAAT Left atrial appendage thrombus, TEE Transesophageal echocardiography, bpm Beats per minute, BMI Body mass index, BSA Body surface area, HF Heart failure, TIA Transient ischemic attack, NYHA New York Heart Association, ACE-I Angiotensin-converting-enzyme inhibitors, ARB Angiotensin receptor blockers, MRA Mineralocorticoid receptor antagonist, LA Left atrium, LAA LA area, LAVI LA volume index, LVEF Left ventricular ejection fraction, E/A The ratio of early to late transmitral diastolic velocities, e’ - pulsed-wave TDI-derived mitral annular early diastolic velocity, PALS Peak atrial longitudinal strain, PACS Peak atrial contraction strain